Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonic anhydrases (CAs) are a family of zinc-containing metalloenzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and protons. They are essential for maintaining acid-base balance, facilitating CO₂ transport, and supporting various physiological processes. At least 16 different alpha-carbonic anhydrase isoforms exist in mammals, each with distinct cellular localization and biophysical properties. They are therapeutic targets for diuretics, anti-glaucoma agents, anticonvulsants, anti-ulcer medications, and anticancer agents.
Inhibition of carbonic anhydrase activity via binding of sulfonamides to the zinc ion at the active site.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbonic Anhydrase Isoenzyme (CA).